Abstract
Soft tissue sarcomas (STS) are a group of different diseases that differ in presentation, response to therapies and prognosis. Some new interesting approaches are becoming available in the treatment of locally advanced as well as metastatic disease, leading to an improvement of patient’s survival. Neoadjuvant chemotherapy has the aim to limit the extension of surgery and to improve the systemic control of the disease and it is currently widely accepted. In the metastatic setting the modern concept of histology-driven therapy has overcome the universal use of the combination of Antracyclines and Ifosfamide in all subtypes of STS.
Some recent chemotherapic agents such as Trabectidine, Eribuline, or targeted compounds such as Pazopanib, Imatinib, Crizotinib, and Sunitinib have a defined role in some specific STS. Olaratumab, an anti PDGFRα monoclonal antibody, has recently been approved in combination with Doxorubicin as first line treatment in metastatic STS. Second line treatment is now adopted in many patients and leads to PFS and TTP improvement. Now-a-days the role of supportive care to increase the activity and to reduce toxicity of chemotherapy is well recognized.
Conversely, despite biological evidence supporting the role of immunotherapy in STS, adoptive and anti check point inhibitors therapies failed to show any activity and different further approaches are awaited.
Citation
Comandone A, Boglione A, Mele T, Bergnolo P and Canton OD. New Perspectives on Therapeutic Approaches in Soft Tissue Sarcomas of the Extremities and Girdles. SM J Sarcoma Res. 2018; 2(1): 1008.